Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Updates from B Cell Trials: Efficacy.

Stanley B Cohen1

  • 1University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas 75235, USA. stanleycohen@radiantresearch.com

The Journal of Rheumatology. Supplement
|May 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

The Journal of rheumatology·2025
Same author

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.

Annals of the rheumatic diseases·2025
Same author

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.

RMD open·2025
Same author

EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Safety profile of JAK inhibitors: a focus on baricitinib.

The Lancet. Rheumatology·2024
Same author

Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.

The Lancet. Rheumatology·2024
Same journal

GRAPPA 2019 Research Recipient Awards Report.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA 2020 Update From the Education Committee.

The Journal of rheumatology. Supplement·2021
Same journal

The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

The Journal of rheumatology. Supplement·2021
See all related articles

B cell targeted therapies, including rituximab and belimumab, show promise for treating rheumatic diseases like rheumatoid arthritis (RA). Clinical trials demonstrate their effectiveness and inform optimal dosing strategies for improved patient outcomes.

Area of Science:

  • Rheumatology and Immunology
  • Clinical Pharmacology
  • Biologics and Targeted Therapies

Background:

  • Rheumatic diseases, particularly rheumatoid arthritis (RA), involve complex immune system dysregulation.
  • B cells are increasingly recognized as key players in the pathogenesis of RA.
  • Targeting B cells offers a potential therapeutic strategy for managing rheumatic conditions.

Purpose of the Study:

  • To review the efficacy and safety data from clinical trials of B cell targeted therapies in rheumatic diseases.
  • To evaluate the effectiveness of specific agents like rituximab and belimumab in RA treatment.
  • To discuss practical aspects of B cell therapy administration and dosing.

Main Methods:

  • Analysis of data from Phase II and Phase III clinical trials, including the DANCER and REFLEX trials.

Related Experiment Videos

  • Evaluation of treatment outcomes based on clinical improvement, symptom reduction, and ACR20 response rates.
  • Review of preliminary results for repeat administration of B cell targeted agents.

    • Main Results:

    • Rituximab (RTX) demonstrated efficacy in RA patients, including those refractory to TNF inhibitors.
    • Different RTX doses showed significant clinical improvement compared to placebo in the DANCER trial.
    • Belimumab achieved a significantly higher ACR20 response rate versus placebo in RA patients.

    Conclusions:

    • B cell targeted therapies are effective in treating rheumatic diseases, supporting the role of B cells in RA pathogenesis.
    • Rituximab and belimumab represent viable treatment options for RA, with established efficacy and safety profiles.
    • Further research and clinical application of B cell therapies are warranted for rheumatic disease management.